AbbVie Hepatitis C combo cures almost all patients in trials


AbbVie's (ABBV) three-drug combo for Hepatitis C cured 96.2-96.3% of patients in two Phase III trials, known as Sapphire-I and Sapphire-II.

The subjects in Sapphire II included those who hadn't responded well to previous treatment.

The regimen includes an Enanta (ENTA) inhibitor. (PR)

See more on Hepatitis C drug studies.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs